Importance Broad-based genomic sequencing is being used more frequently for patients
with advanced non–small cell lung cancer (NSCLC). However, little is known about the …

Background National guidelines have advocated broad molecular profiling as a part of the
standard diagnostic evaluation for advanced non–small cell lung cancer (NSCLC), with the …

Through the rapid acceleration of our understanding of the underlying genetic and
molecular underpinnings of malignancy, in the past 5 years there has been an explosion in …

Background Genetic testing for nonsquamous advanced non–small cell lung cancer
(aNSCLC) is recommended to guide first-line therapy. Activating mutations can be identified …

Purpose To establish a baseline for care and overall survival (OS) based upon
contemporary first-line treatments prescribed in the era before the introduction of immune …

Purpose: Broad, hybrid capture–based next-generation sequencing (NGS), as a clinical test,
uses less tissue to identify more clinically relevant genomic alterations compared with …

Abstract Background. The National Comprehensive Cancer Network (NCCN) guidelines for
patients with metastatic non-small cell lung cancer (NSCLC) recommend testing for EGFR …

Background Molecular profiling of non–small-cell lung cancer (NSCLC) samples has a
profound impact on choice of therapy. However, it is less clear whether EGFR and KRAS …

Objectives There is an expanding list of therapeutically relevant biomarkers for non-small
cell lung cancer (NSCLC), and molecular profiling at diagnosis is paramount. Tissue attrition …

Objectives Molecular diagnosis determines therapeutic strategies for patients with non-small-
cell lung cancer–adenocarcinoma (NSCLC-A) but depends on resources availability. We …